Adam D. Levy

Adam D. Levy is Senior Vice President of Corporate Affairs and Investor Relations at Acrivon Therapeutics, Inc. Previously, he served as Senior Vice President of Investor Relations at Zentalis Pharmaceuticals, Inc. Prior to Zentalis, he was Senior Vice President of Investor Relations and Corporate Communications at Turning Point Therapeutics, where he was part of the team that delivered a $4.1B transaction when the company was acquired by Bristol Myers Squibb in 2022. Earlier in his career he held positions of increasing responsibility in Corporate Strategy and Corporate Development at Pfizer Inc., Novartis AG, Alexion Pharmaceuticals and Gilead Sciences, where he was Head of Corporate Strategy. Adam also served as an Engagement Manager at McKinsey and Company, focusing on supporting clients in the pharmaceutical industry. Adam received an MBA from the Kellogg School of Management at Northwestern University, a PhD in Molecular Biology from the University of Illinois at Chicago, and a BS in Genetics from the University of Illinois at Urbana-Champaign.